Skip to content

UroGen Pharma Ltd

US · URGN #2773 by market cap Listed 2017
27.65 -4.08 -12.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio -10.25 Cheap vs history 31st percentile
5-year average -5.46
P/E ratio -19.98 Cheap vs history 4th percentile
5-year average -4.94 · forward 10.14
P/S ratio 5.13 In line with history 39th percentile
5-year average 6.43 · forward 2.64 · #121 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
UroGen Pharma Ltd (URGN) 1.36B -21.11 -10.83 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value28.54 Economic moatNone UncertaintyVery High

Trading 3.2% below Morningstar's fair value estimate.

Fair value

UroGen Pharma Ltd receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 8% discount to our quantitative fair value estimate of $28.54 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's solid growth increases our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its revenue 3-year growth of 53.1%, which ranks in the top 10% compared with peers globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of -10.3%, a core component of valuation, lies in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

UroGen Pharma Ltd discussion 0 comments

Add a comment